This review provides an integrative and forward-looking perspective on the gamut of coronary physiology for the diagnosis and management of atherosclerosis. Because clinical events serve as the ultimate gold standard, the future of all diagnostic tests, including invasive fractional flow reserve and noninvasive coronary flow reserve, depends on their ability to improve patient outcomes. Given the prominent role of acute coronary syndromes and invasive procedures in cardiology, we practically consider 2 broad categories of patients with coronary disease: acute and stable. For patients with acute coronary disease, coronary physiology may potentially refine treatment of the culprit lesion. For both patients with stable and acute nonculprit disease, reducing hard endpoints with revascularization potentially occurs at the severe end of the focal physiological spectrum, an area under-represented in existing trials. Nonepicardial disease and diffuse atherosclerosis remain underexplored aspects of coronary physiology for testing of novel treatments. Dr. Valentin Fuster. Consequently, we reframe this review as a discussion of an important tool to improve the end goal of patient well-being. To remain practical, we consider 2 broad categories of patients with CAD: acute and stable. For decision-making and ethical, informed discussion with patients, we distinguish among 3 easily understood outcomes: death, MI, and angina.
T his review provides an integrative and forward-looking perspective on the gamut of coronary physiology for the diagnosis and management of atherosclerosis. It ranges from acute coronary syndrome (ACS) as a "perfect storm"
(1,2) of pathophysiological progression (3), visualized as a severe anatomic stenosis (4) benefitting from revascularization, to stable coronary artery disease (CAD) as a complex interplay of focal and diffuse plaque burden (5) . Although atherosclerotic severity and complexity have long been associated with symptoms and risk, a presumed revascularization benefit has not been confirmed using an anatomic assessment.
Rather, we suggest that coronary physiology, with its mechanistic link between intracoronary hemodynamic stress and plaque failure (6) , provides a natural set of tools to quantify both focal and diffuse disease of a severity that may be associated with improved hard outcomes, independent of symptom relief. Accordingly, this review on the future of clinical coronary physiology starts with interventions in ACS, the extreme and final common pathway associated with severe anatomic stenosis, marked flow-pressure abnormalities, and vasomotor dysfunction. From there, we extrapolate from pre-ACS coronary physiology, leading to testable hypotheses for personalized interventions. The Central Illustration provides a visual summary of the paper.
THE GOLD STANDARD
Clinical outcomes serve as the ultimate gold standard for diagnostic tests. Unlike a therapy that directly affects patients, a useful diagnostic test must influence management decisions that in turn alter outcomes. As evidence of this trend, several recent reports highlight the surprisingly small effect of most noninvasive cardiac stress testing on clinical care Consequently, we reframe this review as a discussion of an important tool to improve the end goal of patient well-being. To remain practical, we consider 2 broad categories of patients with CAD: acute and stable. For decision-making and ethical, informed discussion with patients, we distinguish among 3 easily understood outcomes: death, MI, and angina.
Although the most common therapeutic decision made using coronary physiology remains revascularization, we also consider customized medical therapy distinct from treating general risk factors, as detailed later.
PATIENTS WITH ACUTE CORONARY DISEASE
Existing studies of patients with acute coronary disease provide 3 profound, but often overlooked insights for assessing physiologically-guided interventions. First, simultaneous "perfect storms" causing an MI in 2 or more distinct coronary arteries in the same patient are rare. Second, the majority of ACS arises from a very severe lesion that evolved rapidly via sequential, asymptomatic plaque ruptures that healed with progressive stenosis (3, 4, 11) . Third, the long-term risk after revascularized ACS typically returns to the background level of patients with known, but stable CAD. These 3 insights together suggest that nonculprit stenosis in patients with acute coronary disease likely reflects the same background of disease known to exist in patients with stable coronary disease, in contrast to the culprit lesion, whose revascularization without physiological assessment has already been shown to reduce death and MI (12) . As such, the concepts derived for stable CAD likely apply to the nonculprit lesions noted at the time of acute presentation, thereby linking the 2 scenarios. Therefore, this connection and commonality necessitates our initially reviewing acute manifestations.
Acute presentations account for approximately 70% to 80% of the contemporary total number of patients undergoing coronary revascularization (13, 14) , an inversion of the balance from 25 years ago (14) . Due to improved clinical outcomes demon- Depending on the specific intracoronary sensor, either of 2 resistance indexes can be measured:
hyperemic microvascular resistance (HMR) using Doppler flow velocity (25) or the index of microcirculatory resistance (IMR) using bolus thermodilution (26) . Both HMR (27) and IMR (28) Recently, the Danish multicenter PRIMULTI study enrolled 627 patients with STEMI and a significant (over 50% diameter stenosis) nonculprit lesion in a major vessel (36) . generating, yet modestly sized recent trials (<800 patients total) using angiographic criteria alone have suggested marked benefits of 50% to 70% reduction in hard events (34, 35) . By contrast, recent RRR ¼ relative risk reduction; SA ¼ stable angina; STEMI ¼ ST-segment elevation myocardial infarction; UA ¼ unstable angina.
Johnson et al. does not lower the long-term risk of MI" (45) .
Nevertheless, a recent study suggests that this specific aspect regarding the potential benefit of revascularization or alternative treatment strategies is rarely included in informed consent discussions between cardiologists and their patients (46) .
In the future, how will coronary physiology as- Noninvasive CFR (occasionally termed myocardial flow or perfusion reserve, although we prefer CFR to emphasize the fundamental and common physiology) MT ¼ medical therapy; PCI ¼ percutaneous coronary intervention; Pts ¼ patients; other abbreviations as in Figure 1 .
Johnson et al. Historically, the benefit of PCI rested on assumptions that are now challenged by the following 2 realizations. First, visual estimation of stenosis severity performs poorly compared with coronary physiology (43) . Second, unrecognized and unquantified diffuse disease carries a similar risk to focal disease (61, 77) .
This was also illustrated in the PROSPECT study, wherein nonculprit lesions accounted for a comparable frequency of events versus culprit lesions after an ACS (11.6% vs. 12.9% over 3 years, respectively) (11), and in a pooled analysis of post-PCI measurements of FFR that found an inverse relationship with outcomes due to residual diffuse disease (48) .
Although a series of randomized trials has already moved the evaluation of stenosis severity from angiography to physiology, specifically by using FFR (66, 78, 79) , the awareness regarding diffuse and microvascular disease is only now emerging. increased risk of all-cause mortality, respectively, with no differences between men and women (93) . Nils.Johnson@uth.tmc.edu.
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